Global Pulmonary Drugs Market to Surpass US$ 77.31 Billion by 2030 - Coherent Market Insights

SEATTLE, July 15, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global pulmonary drugs market is estimated to be valued at US$ 41.32 billion in 2022 and is expected to exhibit a CAGR of 8.1% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Pulmonary Drugs Market:

Major players operating in market are focusing on adopting inorganic strategies such as acquisition for developing pulmonary drugs. For instance, in November 2021, Sanofi S.A., a Pharmaceutical Company, announced the completion of its acquisition of Kadmon Holdings, Inc. The acquisition further strengthens growth and expansion for the General Medicines portfolio of Sanofi for pulmonary drugs. Sanofi completed its acquisition of Kadmon through the merger of a wholly owned subsidiary of Sanofi with and into Kadmon, pursuant to Section 251 of the General Corporation Law of the State of Delaware, with Kadmon continuing as the surviving corporation and becoming an indirect, wholly owned subsidiary of Sanofi.

Request Sample Copy of this Report at https://www.coherentmarketinsights.com/insight/request-sample/1285

Key Market Takeaways:

Global pulmonary drugs market is expected to exhibit a CAGR of 8.1% during the forecast period due to the increasing prevalence of chronic obstructive pulmonary diseases and other respiratory diseases across the world, which is one of the leading causes of death and disability. Thus, the prevention, treatment, and control of these diseases is one of the top priorities for governments of countries and players in the healthcare sector. According to the World Health Organization, 2017, Chronic Obstructive Pulmonary Diseases (COPD) was responsible for about 5% of the total deaths worldwide in 2015. Furthermore, according to the Office of Disease Prevention and Health Promotion 2014, 25 million patients in the U.S. had asthma that led to an estimated annual expenditure for asthma turning around to US$ 20.7 billion. Moreover, in January 2020, estimated that the global prevalence of COPD was 10·3% in 2019, accounting for 391·9 million cases among people aged 30–79 years, on the basis of the GOLD definition, and 7·6%, accounting for 292·0 million cases.

Among applications, asthma and Chronic Obstructive Pulmonary Disease (COPD) segment holds a dominant position in the pulmonary drugs market, owing to the rising incidence of the condition worldwide.

Key players operating in the global pulmonary drugs market include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZenca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., Alaxia SAS, and Merck Sharp & Dohme Limited.

Request for Customization at https://www.coherentmarketinsights.com/insight/request-customization/1285

Detailed Segmentation:

Global Pulmonary Drugs Market, By Drug Class:

• Inhaled Corticosteroids
• Long Acting Beta-2 Agonists
• Antihistamines
• Vasodilators
• Short Acting Beta-2 Agonists
• Others

Global Pulmonary Drugs Market, By Application:

• Asthma & COPD
• Allergic Rhinitis
• Pulmonary Arterial Hypertension
• Cystic Fibrosis
• Others

Global Pulmonary Drugs Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies 
• E-Commerce

Global Pulmonary Drugs Market, By Region:

•  
• North America
• By Country:
• U.S.
• Canada
• Europe
• By Country:
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country:
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• By Country:
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Middle East & Africa
• By Country:
• GCC Countries
• Israel
• South Africa
• Rest of Middle East & Africa

Buy this Complete Report Now at https://www.coherentmarketinsights.com/insight/buy-now/1285

Find more related trending reports below:

Pulmonary Edema Therapeutics Market, by Drug Class (Diuretics, Opioid Analgesics, Vasodilators, Inotropes, and Others), by Type (Cardiogenic Pulmonary Edema, and Non-cardiogenic Pulmonary Edema), by Route of Administration (Oral and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

Pulmonary Drug Delivery Systems Market, By Product Type (Nebulizers, MDIs, DPIs), By Application (Asthma, COPD, Cystic Fibrosis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 – 2027

Pharmaceutical Drug Delivery Market by Route of administration (Oral Drug Delivery, Topical Drug Delivery, Inhalation Drug Delivery, Pulmonary Drug Delivery, Nasal Drug Delivery, Transmucosal Drug Delivery, Injectable Drug Delivery, Ocular Drug Delivery, and Implantable Drug Delivery), by Application (Infectious Diseases, Cancer, Cardiovascular Diseases, Diabetes, Respiratory Diseases, Central Nervous System Disorders, Autoimmune Diseases, and Others), by End Users (Hospitals, Ambulatory Surgical Centers/Clinics, Diagnostic Centers, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com 
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg